{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T08:50:10Z","timestamp":1788511810131,"version":"build-2803163510"},"reference-count":66,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"funder":[{"name":"DAIDS","award":["UM1AI068633"],"award-info":[{"award-number":["UM1AI068633"]}]},{"name":"DAIDS","award":["UM1AI068615"],"award-info":[{"award-number":["UM1AI068615"]}]},{"name":"DAIDS","award":["UM1AI106707"],"award-info":[{"award-number":["UM1AI106707"]}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["HHSN275201200002I"],"award-info":[{"award-number":["HHSN275201200002I"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>End-user feedback early in product development is important for optimizing multipurpose prevention technologies for HIV and pregnancy prevention. We evaluated the acceptability of the 90-day dapivirine levonorgestrel ring (DPV-LNG ring) used for 14 days compared to a dapivirine-only ring (DVR-200mg) in MTN-030\/IPM 041 (n = 23), and when used for 90 days cyclically or continuously in MTN-044\/IPM 053\/CCN019 (n = 25). We enrolled healthy, non-pregnant, HIV-negative women aged 18\u201345 in Pittsburgh, PA and Birmingham, AL (MTN-030 only). Self-reports of vaginal bleeding and adherence (ring removals, expulsions) were collected via daily short message service. Acceptability data were recorded in face-to-face interviews at study exit. We assessed differences in acceptability by product characteristics and adherence; and associations between baseline characteristics\/demographics, number of bleeding days, adherence, and overall acceptability. Most (21\/23) women in the 14-day MTN-030 study and about half (13\/25) in the 90-day MTN-044 study liked their assigned rings. In MTN-030 there were no significant associations between any variables and overall acceptability of either ring. In MTN-044, women who disliked the DPV-LNG ring had a significantly higher incidence of unanticipated vaginal bleeding, and reporting that vaginal bleeding changes were unacceptable than those who liked it. Although we found no overall association between adherence and acceptability, significantly more women who disliked (versus liked) the DPV-LNG ring reported expulsions during toileting. The DPV-LNG ring could meet the needs of women seeking simultaneous protection from HIV and unintended pregnancy. Addressing issues related to vaginal bleeding and expulsions early in product development will likely enhance acceptability of the DPV-LNG ring.<\/jats:p>\n<jats:p><jats:bold>Trial registration: Clinical Trial Registration:<\/jats:bold> MTN-030\/IPM 041: ClinicalTrials.gov <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02855346\" xlink:type=\"simple\">NCT02855346<\/jats:ext-link>; MTN-044\/IPM 053\/CCN019: ClinicalTrials.gov <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03467347\" xlink:type=\"simple\">NCT03467347<\/jats:ext-link>.<\/jats:p>","DOI":"10.1371\/journal.pone.0312957","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T18:35:38Z","timestamp":1736879738000},"page":"e0312957","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":11,"title":["Acceptability of a dapivirine levonorgestrel vaginal ring in two Phase 1 trials (MTN-030\/IPM 041 and MTN-044\/IPM 053\/CCN019): Implications for multipurpose prevention technology development"],"prefix":"10.1371","volume":"20","author":[{"given":"Barbara A.","family":"Friedland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Gundacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7478-8262","authenticated-orcid":true,"given":"Sharon L.","family":"Achilles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4437-4632","authenticated-orcid":true,"given":"Beatrice A.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Hoesley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbra A.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifton W.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanna","family":"Piper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherri","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brid","family":"Devlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Steytler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Kleinbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bindi","family":"Dangi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chant\u00e9l","family":"Friend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Mensch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"van der Straten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig W.","family":"Hendrix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Blithe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon L.","family":"Hiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the MTN-030\/IPM 041 and MTN-044\/IPM 053\/CCN019 Protocol Teams for the Microbicide Trials Network and the Contraceptive Clinical Trials Network","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,1,14]]},"reference":[{"key":"pone.0312957.ref001","volume-title":"We\u2019ve got the Power: Women, Adolescent Girls and the HIV Response","author":"Joint United Nations Programme on HIV\/AIDS (UNAIDS).","year":"2020"},{"issue":"1","key":"pone.0312957.ref002","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12977-018-0408-3","article-title":"Pre-exposure prophylaxis (PrEP) in an era of stalled HIV prevention: Can it change the game?","volume":"15","author":"R Eakle","year":"2018","journal-title":"Retrovirology."},{"issue":"3","key":"pone.0312957.ref003","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1136\/sextrans-2017-053217","article-title":"Female and younger subjects have lower adherence in PrEP trials: a meta-analysis with implications for the uptake of PrEP service to prevent HIV.","volume":"94","author":"K Yun","year":"2018","journal-title":"Sex Transm Infect"},{"issue":"5","key":"pone.0312957.ref004","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1202614","article-title":"Preexposure prophylaxis for HIV infection among African women.","volume":"367","author":"L Van Damme","year":"2012","journal-title":"New Eng J Med"},{"issue":"6","key":"pone.0312957.ref005","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa1402269","article-title":"Tenofovir-Based Preexposure Prophylaxis for HIV Infection among African Women.","volume":"372","author":"JM Marrazzo","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"pone.0312957.ref006","doi-asserted-by":"crossref","first-page":"e0227632","DOI":"10.1371\/journal.pone.0227632","article-title":"Key barriers and enablers associated with uptake and continuation of oral pre-exposure prophylaxis (PrEP) in the public sector in Zimbabwe: Qualitative perspectives of general population clients at high risk for HIV.","volume":"15","author":"MM Gombe","year":"2020","journal-title":"PLoS one"},{"issue":"1","key":"pone.0312957.ref007","doi-asserted-by":"crossref","first-page":"e25872","DOI":"10.1002\/jia2.25872","article-title":"HIV prevention: better choice for better coverage.","volume":"25","author":"LG Bekker","year":"2022","journal-title":"J Int AIDS Soc"},{"issue":"9","key":"pone.0312957.ref008","doi-asserted-by":"crossref","first-page":"e1002885","DOI":"10.1371\/journal.pmed.1002885","article-title":"Integrating preexposure prophylaxis delivery in routine family planning clinics: A feasibility programmatic evaluation in Kenya.","volume":"16","author":"KK Mugwanya","year":"2019","journal-title":"PLoS Med."},{"key":"pone.0312957.ref009","volume-title":"Access to the Dapivirine Vaginal Ring: A timeline on progress","author":"AVAC","year":"2022"},{"key":"pone.0312957.ref010","volume-title":"Dapivirine Vaginal Ring 25 mg: Opinion on medicine for use outside E","author":"European Medicines Agency","year":"2021"},{"issue":"22","key":"pone.0312957.ref011","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa1602046","article-title":"Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women","volume":"375","author":"A Nel","year":"2016","journal-title":"N Engl J Med"},{"issue":"22","key":"pone.0312957.ref012","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1056\/NEJMoa1506110","article-title":"Use of a vaginal ring containing dapivirine for HIV-1 prevention in women","volume":"375","author":"J Baeten","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"pone.0312957.ref013","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1016\/S2352-3018(20)30304-0","article-title":"Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study.","volume":"8","author":"JM Baeten","year":"2021","journal-title":"Lancet HIV"},{"issue":"2","key":"pone.0312957.ref014","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1016\/S2352-3018(20)30300-3","article-title":"Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study.","volume":"8","author":"A Nel","year":"2021","journal-title":"Lancet HIV"},{"issue":"11","key":"pone.0312957.ref015","doi-asserted-by":"crossref","first-page":"e25634","DOI":"10.1002\/jia2.25634","article-title":"Greater dapivirine release from the dapivirine vaginal ring is correlated with lower risk of HIV\u20101 acquisition: a secondary analysis from a randomized, placebo\u2010controlled trial","volume":"23","author":"ER Brown","year":"2020","journal-title":"J Int AIDS Soc"},{"issue":"7","key":"pone.0312957.ref016","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1007\/s10461-022-03951-8","article-title":"Women Want Choices: Opinions from the Share.Learn.Shape Global Internet Survey About Multipurpose Prevention Technology (MPT) Products in Development.","volume":"27","author":"BA Friedland","year":"2023","journal-title":"AIDS Behav."},{"issue":"3","key":"pone.0312957.ref017","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.contraception.2017.10.006","article-title":"Interest in multipurpose prevention technologies to prevent HIV\/STIs and unintended pregnancy among young women in the United States.","volume":"97","author":"JS Hynes","year":"2018","journal-title":"Contraception."},{"key":"pone.0312957.ref018","volume-title":"Assessing the potential of MPTs in Uganda, Nigeria and South Africa.","author":"IPSOS","year":"2014"},{"issue":"3","key":"pone.0312957.ref019","doi-asserted-by":"crossref","first-page":"e25094","DOI":"10.1002\/jia2.25094","article-title":"The Tablets, Ring, Injections as Options (TRIO) study: what young African women chose and used for future HIV and pregnancy prevention.","volume":"21","author":"A van der Straten","year":"2018","journal-title":"J Int AIDS Soc"},{"issue":"1","key":"pone.0312957.ref020","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10461-017-1913-4","article-title":"A Randomized Crossover Study Evaluating the Use and Acceptability of the SILCS Diaphragm Compared to Vaginal Applicators for Vaginal Gel Delivery","volume":"22","author":"M Beksinska","year":"2018","journal-title":"AIDS Behav"},{"issue":"5","key":"pone.0312957.ref021","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/1471-0528.12842","article-title":"The need for multipurpose prevention technologies in sub-Saharan Africa.","volume":"121","author":"SA Karim","year":"2014","journal-title":"BJOG."},{"issue":"2","key":"pone.0312957.ref022","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s10461-017-1977-1","article-title":"Impact of the Dapivirine Vaginal Ring on Sexual Experiences and Intimate Partnerships of Women in an HIV Prevention Clinical Trial: Managing Ring Detection and Hot Sex","volume":"22","author":"ND Laborde","year":"2018","journal-title":"AIDS Behav. 2017\/11\/21 ed."},{"key":"pone.0312957.ref023","article-title":"MPT Product Development Database","author":"IMPT for Reproductive Health","year":"2022","journal-title":"IMPT for Reproductive Health"},{"issue":"2","key":"pone.0312957.ref024","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.contraception.2010.07.008","article-title":"Vaginal ring contraception.","volume":"83","author":"J Kerns","year":"2011","journal-title":"Contraception."},{"issue":"15","key":"pone.0312957.ref025","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1080\/14656566.2018.1519549","article-title":"Advances in contraceptive vaginal rings: what does the future hold?","volume":"19","author":"I Monteiro","year":"2018","journal-title":"Expert Opin Pharmacother."},{"key":"pone.0312957.ref026","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.2147\/DDDT.S133170","article-title":"Historical development of vaginal microbicides to prevent sexual transmission of HIV in women: from past failures to future hopes","volume":"11","author":"F Notario-P\u00e9rez","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"pone.0312957.ref027","author":"Data on File: International Partnership for Microbicides (IPM).","year":"2022","journal-title":"Investigator\u2019s Brochure: Dapivirine Vaginal Ring (Version 15.0)."},{"key":"pone.0312957.ref028","article-title":"Investigator\u2019s Brochure: Dapivirine-Levonorgestrel Vaginal Ring (Version 9.0).","author":"Data on File: International Partnership for Microbicides (IPM).","year":"2021"},{"key":"pone.0312957.ref029","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jconrel.2016.02.020","article-title":"Controlling levonorgestrel binding and release in a multi-purpose prevention technology vaginal ring device","volume":"226","author":"DJ Murphy","year":"2016","journal-title":"J Control Release"},{"key":"pone.0312957.ref030","doi-asserted-by":"crossref","first-page":"118574","DOI":"10.1016\/j.ijpharm.2019.118574","article-title":"Towards a dapivirine and levonorgestrel multipurpose vaginal ring: Investigations into the reaction between levonorgestrel and addition-cure silicone elastomers","volume":"569","author":"YH Dallal Bashi","year":"2019","journal-title":"Int J Pharm"},{"key":"pone.0312957.ref031","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.addr.2015.02.004","article-title":"Acceptability and preferences for vaginal dosage forms intended for prevention of HIV or HIV and pregnancy","volume":"92","author":"C Woodsong","year":"2015","journal-title":"Adv Drug Deliv Rev"},{"issue":"10\u201311","key":"pone.0312957.ref032","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1089\/aid.2015.0275","article-title":"Perceptibility and the \u201cChoice Experience\u201d: User Sensory Perceptions and Experiences Inform Vaginal Prevention Product Design.","volume":"32","author":"KM Guthrie","year":"2016","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"6","key":"pone.0312957.ref033","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.contraception.2015.08.007","article-title":"Meaning-making matters in product design: users\u2019 sensory perceptions and experience evaluations of long-acting vaginal gels and intravaginal rings.","volume":"92","author":"RK Rosen","year":"2015","journal-title":"Contraception."},{"issue":"1","key":"pone.0312957.ref034","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10461-017-1911-6","article-title":"End-Users\u2019 Product Preference Across Three Multipurpose Prevention Technology Delivery Forms: Baseline Results from Young Women in Kenya and South Africa","volume":"22","author":"R Weinrib","year":"2018","journal-title":"AIDS Behav"},{"issue":"6","key":"pone.0312957.ref035","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s13346-017-0385-4","article-title":"On-demand Microbicide Products: Design Matters.","volume":"7","author":"SK Patel","year":"2017","journal-title":"Drug Deliv Transl Res."},{"issue":"6","key":"pone.0312957.ref036","doi-asserted-by":"crossref","first-page":"e0304552","DOI":"10.1371\/journal.pone.0304552","article-title":"Phase 1 randomized trials to assess safety, pharmacokinetics, and vaginal bleeding associated with use of extended duration dapivirine and levonorgestrel vaginal rings.","volume":"19","author":"SL Achilles","year":"2024","journal-title":"PLoS One."},{"issue":"6","key":"pone.0312957.ref037","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1097\/COH.0b013e3283590632","article-title":"Acceptability in microbicide and PrEP trials: current status and a reconceptualization.","volume":"7","author":"BS Mensch","year":"2012","journal-title":"Curr Opin HIV AIDS"},{"key":"pone.0312957.ref038","doi-asserted-by":"crossref","first-page":"1147628","DOI":"10.3389\/frph.2023.1147628","article-title":"Participant experiences with a multipurpose vaginal ring for HIV and pregnancy prevention during a phase 1 clinical trial: learning from users to improve acceptability.","volume":"5","author":"MK Shapley-Quinn","year":"2023","journal-title":"Front Reprod Health"},{"issue":"6","key":"pone.0312957.ref039","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/j.1365-2516.2012.02869.x","article-title":"Feasibility of short message service to document bleeding episodes in children with haemophilia","volume":"18","author":"CR Broderick","year":"2012","journal-title":"Haemophilia"},{"issue":"6","key":"pone.0312957.ref040","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.contraception.2015.09.004","article-title":"A randomized controlled trial of daily text messages versus monthly paper diaries to collect bleeding data after intrauterine device insertion.","volume":"92","author":"S Nippita","year":"2015","journal-title":"Contraception."},{"issue":"6","key":"pone.0312957.ref041","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.contraception.2019.02.004","article-title":"Bleeding and spotting with the levonorgestrel 13.5 mg intrauterine system: the impact of insertion timing.","volume":"99","author":"N Shimoni","year":"2019","journal-title":"Contraception"},{"issue":"10","key":"pone.0312957.ref042","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1136\/jech.2008.085316","article-title":"Randomised controlled trial of paper, online and SMS diaries for collecting sexual behaviour information from young people","volume":"64","author":"MSC Lim","year":"2010","journal-title":"J Epidemiol Community Health"},{"issue":"7","key":"pone.0312957.ref043","doi-asserted-by":"crossref","first-page":"e11600","DOI":"10.1371\/journal.pone.0011600","article-title":"A mixed methods and triangulation model for increasing the accuracy of adherence and sexual behaviour data: the Microbicides Development Programme.","volume":"5","author":"R Pool","year":"2010","journal-title":"PLoS One"},{"issue":"3Suppl 2","key":"pone.0312957.ref044","doi-asserted-by":"crossref","first-page":"19158","DOI":"10.7448\/IAS.17.3.19158","article-title":"An interdisciplinary framework for measuring and supporting adherence in HIV prevention trials of ARV-based vaginal rings","volume":"17","author":"KM MacQueen","year":"2014","journal-title":"J Int AIDS Soc"},{"key":"pone.0312957.ref045","author":"International Partnership for Microbicides, Inc.","year":"2022","journal-title":"A Randomized, Double-Blind, Phase 1b Study in Healthy HIV-Negative Women to Evaluate the Pharmacokinetics, Safety, and Bleeding Patterns Associated With 90-Day Use of Core-Sheath Vaginal Rings Releasing Dapivirine and Levonorgestrel ["},{"issue":"5","key":"pone.0312957.ref046","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1089\/aid.2016.0167","article-title":"A Comparative Pre-Phase I Study of the Impact of Gel Vehicle Volume on Distal Colon Distribution, User Experience, and Acceptability","volume":"33","author":"ED Weld","year":"2017","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"5","key":"pone.0312957.ref047","doi-asserted-by":"crossref","first-page":"e0197269","DOI":"10.1371\/journal.pone.0197269","article-title":"User evaluations offer promise for pod-intravaginal ring as a drug delivery platform: A mixed methods study of acceptability and use experiences.","volume":"13","author":"KM Guthrie","year":"2018","journal-title":"PLoS One"},{"issue":"12","key":"pone.0312957.ref048","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1089\/aid.2020.0138","article-title":"The Role of Volume in the Perceptibility of Topical Vaginal Formulations: User Sensory Perceptions and Experiences of Heterosexual Couples During Vaginal Sex","volume":"36","author":"KM Guthrie","year":"2020","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"5","key":"pone.0312957.ref049","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s13346-017-0397-0","article-title":"User input in iterative design for prevention product development: leveraging interdisciplinary methods to optimize effectiveness.","volume":"7","author":"KM Guthrie","year":"2017","journal-title":"Drug Deliv Transl Res"},{"issue":"7","key":"pone.0312957.ref050","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1089\/aid.2021.0038","article-title":"Designing Dual Compartment HIV Prevention Products: Women\u2019s Sensory Perceptions and Experiences of Suppositories for Rectal and Vaginal Use","volume":"38","author":"KM Guthrie","year":"2022","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"8","key":"pone.0312957.ref051","doi-asserted-by":"crossref","first-page":"e25170","DOI":"10.1002\/jia2.25170","article-title":"Perspectives of South African youth in the development of an implant for HIV prevention","volume":"21","author":"EA Krogstad","year":"2018","journal-title":"J Int AIDS Soc"},{"issue":"6","key":"pone.0312957.ref052","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1007\/s10461-018-2336-6","article-title":"Rectal Douching Practices Associated with Anal Intercourse: Implications for the Development of a Behaviorally Congruent HIV-Prevention Rectal Microbicide Douche.","volume":"23","author":"A Carballo-Dieguez","year":"2019","journal-title":"AIDS Behav"},{"issue":"2","key":"pone.0312957.ref053","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/13625187.2017.1287351","article-title":"Efficacy and side-effects profile of the ethinylestradiol and etonogestrel contraceptive vaginal ring: a systematic review and meta-analysis.","volume":"22","author":"A L\u00f3pez-Picado","year":"2017","journal-title":"Eur J Contracept Reprod Health Care.Apr"},{"issue":"22","key":"pone.0312957.ref054","first-page":"11810","article-title":"Safety, efficacy and quality of life of the novel vaginal contraceptive ring containing etonogestrel\/ethinylestradiol 11.0\/3.474 mg after 3 years of \u201creal life\u201d experience.","volume":"24","author":"A M\u00fcller","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci."},{"issue":"1","key":"pone.0312957.ref055","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/13625180701577122","article-title":"Cycle control, tolerability, efficacy and acceptability of the vaginal contraceptive ring, NuvaRing: results of clinical experience in Germany.","volume":"13","author":"C Brucker","year":"2008","journal-title":"Eur J Contracept Reprod Health Care."},{"key":"pone.0312957.ref056","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ejogrb.2016.05.009","article-title":"Efficacy of combined hormonal vaginal ring in comparison to combined hormonal pills in heavy menstrual bleeding.","volume":"203","author":"P Dahiya","year":"2016","journal-title":"Eur J Obstet Gynecol Reprod Biol."},{"issue":"19","key":"pone.0312957.ref057","first-page":"7204","article-title":"Multicenter, international observational study on quality of life and acceptability of a vaginal contraceptive ring containing etonogestrel\/ethinylestradiol 11.00\/3.474 mg over six months of use.","volume":"26","author":"S Palacios","year":"2022","journal-title":"Eur Rev Med Pharmacol Sci."},{"issue":"2","key":"pone.0312957.ref058","first-page":"105","article-title":"Microdose intravaginal levonorgestrel contraception: a multicentre clinical trial. I. Contraceptive efficacy and side effects. World Health Organization. Task Force on Long-Acting Systemic Agents for Fertility Regulation","volume":"41","author":"S Koetsawang","year":"1990","journal-title":"Contraception."},{"key":"pone.0312957.ref059","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2147\/IJWH.S6162","article-title":"Examining the efficacy, safety, and patient acceptability of the combined contraceptive vaginal ring (NuvaRing).","volume":"2","author":"DR Wieder","year":"2010","journal-title":"Int J Womens Health."},{"issue":"5","key":"pone.0312957.ref060","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.contraception.2017.12.011","article-title":"Factors associated with nonadherence to instructions for using the Nestorone\u00ae\/ethinyl estradiol contraceptive vaginal ring.","volume":"97","author":"BM Stifani","year":"2018","journal-title":"Contraception."},{"key":"pone.0312957.ref061","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.contraception.2021.10.001","article-title":"Vaginal ring acceptability: A systematic review and meta-analysis of vaginal ring experiences from around the world.","volume":"106","author":"K Ridgeway","year":"2022","journal-title":"Contraception."},{"issue":"11","key":"pone.0312957.ref062","doi-asserted-by":"crossref","first-page":"e0224898","DOI":"10.1371\/journal.pone.0224898","article-title":"Vaginal ring acceptability and related preferences among women in low- and middle-income countries: A systematic review and narrative synthesis.","volume":"14","author":"JB Griffin","year":"2019","journal-title":"PLoS One."},{"issue":"3","key":"pone.0312957.ref063","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/sifp.12209","article-title":"Barriers and Enablers Influencing Women\u2019s Adoption and Continuation of Vaginally Inserted Contraceptive Methods: A Literature Review.","volume":"53","author":"DM Harris","year":"2022","journal-title":"Stud Fam Plann."},{"key":"pone.0312957.ref064","doi-asserted-by":"crossref","first-page":"799963","DOI":"10.3389\/fgwh.2021.799963","article-title":"Acceptability and Satisfaction of Contraceptive Vaginal Rings in Clinical Studies: A Systematic Review and Narrative Synthesis.","volume":"2","author":"T Delvaux","year":"2021","journal-title":"Front Glob Womens Health."},{"issue":"11","key":"pone.0312957.ref065","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1080\/17425247.2020.1798927","article-title":"The ins and outs of drug-releasing vaginal rings: a literature review of expulsions and removals.","volume":"17","author":"P Boyd","year":"2020","journal-title":"Expert Opin Drug Deliv."},{"key":"pone.0312957.ref066","doi-asserted-by":"crossref","first-page":"682689","DOI":"10.3389\/frph.2021.682689","article-title":"The Promise of the Dual Prevention Pill: A Framework for Development and Introduction.","volume":"3","author":"BA Friedland","year":"2021","journal-title":"Front Reprod Health"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0312957","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T18:36:06Z","timestamp":1736879766000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0312957"}},"subtitle":[],"editor":[{"given":"Jos\u00e9","family":"das Neves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,1,14]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0312957","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,14]]}}}